2
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Effects on brain tumor cell proliferation by an adenovirus vector that bears the Interleukin-4 gene

, , , &
Pages 237-241 | Received 03 Sep 1997, Accepted 15 Dec 1997, Published online: 05 Aug 2009
 

Abstract

A recombinant adenovirus vector bearing the IL-4 gene (AD-IL-4) was used to infect rat glioma C6 cells in culture at multiplicity of infections (MOI) from 50 to 1800. C6 cell proliferation was not altered significantly by adenoviral infection. However, IL-4 production increased in a dose-dependent manner. To ascertain effects on in vivo cell proliferation, a subcutaneous tumor model was used. Rat C6 glioma cells alone or C6 mixed with the control virus bearing the LacZ gene (Ad-LacZ) produced tumors that measured an average of approximately 3000 mm3 35 days after implantation. In contrast, C6 cells mixed with Ad-IL-4 produced significant inhibition of tumor growth (P=0.035 compared to C6 tumor; P=0.023 compared to C6+Ad-LacZ tumor. Student's t test). IL-4 levels in mice serum were measured by ELISA and reached a peak of approximately 700 pg/ml at 14 days. These preliminary results showed that adenovirus-mediated delivery of the IL-4 gene may result in a significant inhibition of rat C6 cell tumor growth. Further studies will be necessary to refine this anti-tumor effect for as a potential therapy for cancer.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.